Imarem 100 And Imarem 400 100 mg and 400 mg FC tablets
PDF Leaflet Revision Date: 29 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various hematological malignancies including CML and Ph+ ALL.
Dosage (summary)
400 mg/day for chronic phase CML; 600 mg/day for accelerated phase or blast crisis; 800 mg/day for DFSP.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Safety not established; avoid breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors increase imatinib levels
- CYP3A4 inducers decrease imatinib levels
Contraindications
- Hypersensitivity to imatinib
Common side effects
- Neutropenia
- Thrombocytopenia
- Nausea
- Vomiting
- Fluid retention
Counselling Points
- Take with food and water
- Monitor for signs of liver dysfunction
- Use contraception during treatment
Serious warnings
- Cerebrovascular events
- Hepatotoxicity
- Fluid retention
- Tumor lysis syndrome
Important Disclaimer
The Imarem 100 And Imarem 400 100 mg and 400 mg FC tablets professional information leaflet below is the property of Innovata Pharmaceuticals Pty (Ltd) and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
